Applied Surface Science, ISSN 0169-4332, 01/2019, Volume 465, pp. 172 - 179
This work studies the adsorption properties of Pd(1 1 1) surface to various SF decomposition components (H S, SO , SOF , and SO F ). Due to the affluent active...
Surface adsorption | Pd(1 1 1) adsorbent | SF6 decomposition components | DFT calculations
Surface adsorption | Pd(1 1 1) adsorbent | SF6 decomposition components | DFT calculations
Journal Article
Asian Pacific Journal of Cancer Prevention, ISSN 1513-7368, 03/2018, Volume 19, Issue 3, pp. 693 - 698
Background: Positive and negative co-stimulatory molecules are important factors determining the outcome of immune responses to the presence of tumors. Since...
PD.1 | Colon cancer | ICOS | Polymorphism | polymorphism
PD.1 | Colon cancer | ICOS | Polymorphism | polymorphism
Journal Article
Pigment Cell & Melanoma Research, ISSN 1755-1471, 05/2015, Volume 28, Issue 3, pp. 245 - 253
Summary This study evaluated the expression of PD‐L1 in immunotherapy‐naïve metastatic melanoma patients to determine longitudinal intrapatient concordance and...
pathology | metastasis | immunotherapy | diagnosis | melanoma | PD‐1 | biomarker | prognosis | heterogeneity | PD‐L1 | Heterogeneity | Pathology | Biomarker | Prognosis | Immunotherapy | Melanoma | PD-L1 | Diagnosis | Metastasis | PD-1 | SURVIVAL | INDEPENDENT PREDICTOR | SAFETY | ANTIBODY | CELL BIOLOGY | DERMATOLOGY | ONCOLOGY | UP-REGULATION | TUMOR MICROENVIRONMENT | Immunohistochemistry | Melanoma - metabolism | Skin Neoplasms - pathology | Skin Neoplasms - immunology | Humans | Middle Aged | Male | Clinical Trials as Topic | Melanoma - pathology | Genetic Heterogeneity | Skin Neoplasms - metabolism | B7-H1 Antigen - metabolism | Neoplasm Metastasis | Neoplasm Grading | Melanoma - immunology | Survival Analysis | Female | Lymphocytes, Tumor-Infiltrating - immunology | Clinical trials | Medical research | Tumors
pathology | metastasis | immunotherapy | diagnosis | melanoma | PD‐1 | biomarker | prognosis | heterogeneity | PD‐L1 | Heterogeneity | Pathology | Biomarker | Prognosis | Immunotherapy | Melanoma | PD-L1 | Diagnosis | Metastasis | PD-1 | SURVIVAL | INDEPENDENT PREDICTOR | SAFETY | ANTIBODY | CELL BIOLOGY | DERMATOLOGY | ONCOLOGY | UP-REGULATION | TUMOR MICROENVIRONMENT | Immunohistochemistry | Melanoma - metabolism | Skin Neoplasms - pathology | Skin Neoplasms - immunology | Humans | Middle Aged | Male | Clinical Trials as Topic | Melanoma - pathology | Genetic Heterogeneity | Skin Neoplasms - metabolism | B7-H1 Antigen - metabolism | Neoplasm Metastasis | Neoplasm Grading | Melanoma - immunology | Survival Analysis | Female | Lymphocytes, Tumor-Infiltrating - immunology | Clinical trials | Medical research | Tumors
Journal Article
Immunological Reviews, ISSN 0105-2896, 07/2010, Volume 236, Issue 1, pp. 219 - 242
Regulatory T cells (Tregs) and the PD‐1: PD‐ligand (PD‐L) pathway are both critical to terminating immune responses. Elimination of either can result in the...
regulatory T cells | PD‐1 | PD‐L2 | Foxp3 | PD‐L1 | PD-L1 | PD-L2 | Regulatory T cells | PD-1 | COLLAGEN-INDUCED ARTHRITIS | PROGRAMMED DEATH-1 PD-1 | IMMUNOLOGY | CHRONIC VIRAL-INFECTION | INDUCED UP-REGULATION | NONOBESE DIABETIC MICE | TRANSCRIPTION FACTOR FOXP3 | REGULATORY T-CELLS | CENTRAL-NERVOUS-SYSTEM | GASTRIC EPITHELIAL-CELLS | SCURFY MOUSE MUTANT | Antigens, CD - immunology | T-Lymphocytes, Regulatory - metabolism | Apoptosis Regulatory Proteins - immunology | B7-H1 Antigen | Humans | Autoimmune Diseases - immunology | Antigens, CD - metabolism | Apoptosis Regulatory Proteins - metabolism | T-Lymphocytes, Regulatory - immunology | Signal Transduction - immunology | Models, Immunological | Animals | Autoimmunity - immunology | Immune Tolerance - immunology | Programmed Cell Death 1 Receptor | Autoimmune Diseases - metabolism | Autoimmunity | T cells | Tregs
regulatory T cells | PD‐1 | PD‐L2 | Foxp3 | PD‐L1 | PD-L1 | PD-L2 | Regulatory T cells | PD-1 | COLLAGEN-INDUCED ARTHRITIS | PROGRAMMED DEATH-1 PD-1 | IMMUNOLOGY | CHRONIC VIRAL-INFECTION | INDUCED UP-REGULATION | NONOBESE DIABETIC MICE | TRANSCRIPTION FACTOR FOXP3 | REGULATORY T-CELLS | CENTRAL-NERVOUS-SYSTEM | GASTRIC EPITHELIAL-CELLS | SCURFY MOUSE MUTANT | Antigens, CD - immunology | T-Lymphocytes, Regulatory - metabolism | Apoptosis Regulatory Proteins - immunology | B7-H1 Antigen | Humans | Autoimmune Diseases - immunology | Antigens, CD - metabolism | Apoptosis Regulatory Proteins - metabolism | T-Lymphocytes, Regulatory - immunology | Signal Transduction - immunology | Models, Immunological | Animals | Autoimmunity - immunology | Immune Tolerance - immunology | Programmed Cell Death 1 Receptor | Autoimmune Diseases - metabolism | Autoimmunity | T cells | Tregs
Journal Article
Annual Review of Immunology, ISSN 0732-0582, 2008, Volume 26, Issue 1, pp. 677 - 704
Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals that regulate the balance between T cell activation, tolerance, and...
Autoimmunity | Infectious disease | Tumor | Costimulation | T cell | RESPONSES IN-VIVO | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | SYSTEMIC-LUPUS-ERYTHEMATOSUS | DENDRITIC CELLS | CHRONIC HEPATITIS-B | IMMUNOLOGY | GAMMA-DEPENDENT MECHANISM | CROSS-LINKING ANTIBODY | costimulation | autoimmunity | infectious disease | tumor | PROGRAMMED DEATH-1 PATHWAY | T-CELL-ACTIVATION | GASTRIC EPITHELIAL-CELLS | Immunity - physiology | Models, Immunological | Animals | B7-H1 Antigen | Humans | B7-1 Antigen - physiology | Antigens, CD - physiology | Apoptosis Regulatory Proteins - physiology | Ligands | Programmed Cell Death 1 Receptor | Self Tolerance - physiology
Autoimmunity | Infectious disease | Tumor | Costimulation | T cell | RESPONSES IN-VIVO | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | SYSTEMIC-LUPUS-ERYTHEMATOSUS | DENDRITIC CELLS | CHRONIC HEPATITIS-B | IMMUNOLOGY | GAMMA-DEPENDENT MECHANISM | CROSS-LINKING ANTIBODY | costimulation | autoimmunity | infectious disease | tumor | PROGRAMMED DEATH-1 PATHWAY | T-CELL-ACTIVATION | GASTRIC EPITHELIAL-CELLS | Immunity - physiology | Models, Immunological | Animals | B7-H1 Antigen | Humans | B7-1 Antigen - physiology | Antigens, CD - physiology | Apoptosis Regulatory Proteins - physiology | Ligands | Programmed Cell Death 1 Receptor | Self Tolerance - physiology
Journal Article
EMBO molecular medicine, ISSN 1757-4676, 07/2019, Volume 11, Issue 7, p. e10293
The majority of lung cancer patients progressing from conventional therapies are refractory to PD-L1/PD-1 blockade monotherapy. Here, we show that baseline...
lung cancer | Immunology | B7‐H1 | immunotherapy | biomarker | PD‐1 | PD‐L1 | Cancer
lung cancer | Immunology | B7‐H1 | immunotherapy | biomarker | PD‐1 | PD‐L1 | Cancer
Journal Article
Journal of Hepato‐Biliary‐Pancreatic Sciences, ISSN 1868-6974, 06/2019, Volume 26, Issue 6, pp. 242 - 243
Highlight Tanaka and Kubo reported the first case of recurrent occupational cholangiocarcinoma treated with programmed death‐1 inhibitor. A programmed death‐1...
Occupational cholangiocarcinoma | Programmed death‐ligand 1 | PD‐1 inhibitor | CA19‐9 | Nivolumab
Occupational cholangiocarcinoma | Programmed death‐ligand 1 | PD‐1 inhibitor | CA19‐9 | Nivolumab
Journal Article
The Oncologist, ISSN 1083-7159, 05/2016, Volume 21, Issue 5, pp. 634 - 642
On October 9, 2015, the U.S. Food and Drug Administration expanded the nivolumab metastatic non‐small cell lung cancer (NSCLC) indication to include patients...
Non‐small cell lung carcinoma | PD‐1 inhibitor | Nivolumab | Immunotherapy | Non-small cell lung carcinoma | PD-1 inhibitor | TRIAL | ONCOLOGY | BLOCKADE | DOCETAXEL | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | United States | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Drug Approval | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Taxoids - therapeutic use | Neoplasm Metastasis | Aged, 80 and over | Adult | Female | Aged | B7-H1 Antigen - analysis | Carcinoma, Non-Small-Cell Lung - drug therapy | United States Food and Drug Administration | FDA | Regulatory Issues
Non‐small cell lung carcinoma | PD‐1 inhibitor | Nivolumab | Immunotherapy | Non-small cell lung carcinoma | PD-1 inhibitor | TRIAL | ONCOLOGY | BLOCKADE | DOCETAXEL | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | United States | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Drug Approval | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Taxoids - therapeutic use | Neoplasm Metastasis | Aged, 80 and over | Adult | Female | Aged | B7-H1 Antigen - analysis | Carcinoma, Non-Small-Cell Lung - drug therapy | United States Food and Drug Administration | FDA | Regulatory Issues
Journal Article
Pathologe, ISSN 0172-8113, 11/2018, Volume 39, Issue 6, pp. 546 - 555
Journal Article
American Journal of Transplantation, ISSN 1600-6135, 10/2012, Volume 12, Issue 10, pp. 2575 - 2587
Understanding immunoregulatory mechanisms is essential for the development of novel interventions to improve long‐term allograft survival. Programmed death 1...
regulatory T cells | costimulation | transplantation | PD‐1 | PD‐L2 | tolerance | Alloimmunity | PD‐L1 | PD-L1 | PD-L2 | PD-1 | SURGERY | FOXP3 EXPRESSION | ALLOGRAFT-REJECTION | DENDRITIC CELLS | PROGRAMMED DEATH LIGAND-1 | TISSUE EXPRESSION | CUTTING EDGE | POSITIVE SELECTION | COSTIMULATORY PATHWAYS | REGULATORY T-CELLS | ANTIBODY-RESPONSES | Signal Transduction | Lymphocyte Activation | Humans | Immune Tolerance | Programmed Cell Death 1 Receptor - metabolism | Graft Survival | Organ Transplantation | Programmed Cell Death 1 Receptor - physiology | T-Lymphocytes, Regulatory - immunology | T cells | Analysis | alloimmunity
regulatory T cells | costimulation | transplantation | PD‐1 | PD‐L2 | tolerance | Alloimmunity | PD‐L1 | PD-L1 | PD-L2 | PD-1 | SURGERY | FOXP3 EXPRESSION | ALLOGRAFT-REJECTION | DENDRITIC CELLS | PROGRAMMED DEATH LIGAND-1 | TISSUE EXPRESSION | CUTTING EDGE | POSITIVE SELECTION | COSTIMULATORY PATHWAYS | REGULATORY T-CELLS | ANTIBODY-RESPONSES | Signal Transduction | Lymphocyte Activation | Humans | Immune Tolerance | Programmed Cell Death 1 Receptor - metabolism | Graft Survival | Organ Transplantation | Programmed Cell Death 1 Receptor - physiology | T-Lymphocytes, Regulatory - immunology | T cells | Analysis | alloimmunity
Journal Article
11.
Full Text
Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising?
Cancer, ISSN 0008-543X, 12/2019, Volume 125, Issue S24, pp. 4616 - 4622
Despite advances in surgery and chemotherapy and the integration of antivascular endothelial growth factor therapy as well as poly(adenosine...
immunotherapy combinations | antiprogrammed cell death protein 1 (anti‐PD‐1) | ovarian cancer | immunotherapy | antiprogrammed death‐ligand 1 (anti‐PD‐L1) | checkpoint inhibitor
immunotherapy combinations | antiprogrammed cell death protein 1 (anti‐PD‐1) | ovarian cancer | immunotherapy | antiprogrammed death‐ligand 1 (anti‐PD‐L1) | checkpoint inhibitor
Journal Article
British Journal of Haematology, ISSN 0007-1048, 08/2019, Volume 186, Issue 3, pp. e41 - e44
Journal Article
International Journal of Cancer, ISSN 0020-7136, 04/2015, Volume 136, Issue 7, pp. 1494 - 1503
Due to the generally poor prognosis of head and neck squamous cell carcinoma (HNSCC), treatment has been intensified, these last decades, leading to an...
PD‐1:PD‐L1 immune checkpoint | PI3K pathway | oropharyngeal cancers | human papillomavirus | treatment de‐escalation | Oropharyngeal cancers | Treatment de-escalation | Human papillomavirus | PD-1:PD-L1 immune checkpoint | SQUAMOUS-CELL-CARCINOMA | GYNECOLOGIC-ONCOLOGY-GROUP | INDUCTION CHEMOTHERAPY | treatment de-escalation | ROBOTIC SURGERY | HUMAN-PAPILLOMAVIRUS | INTRAEPITHELIAL NEOPLASIA | CANCER | PHASE-II TRIAL | ONCOLOGY | LOCALLY ADVANCED HEAD | SELECTIVE NECK DISSECTION | Oropharyngeal Neoplasms - therapy | Cancer Vaccines - therapeutic use | Papillomavirus Infections - complications | Humans | Oropharyngeal Neoplasms - etiology | Treatment Outcome | Clinical Trials as Topic | Combined Modality Therapy | Clinical trials | Papillomavirus infections | Squamous cell carcinoma | Laryngeal cancer | Cancer therapies | Index Medicus
PD‐1:PD‐L1 immune checkpoint | PI3K pathway | oropharyngeal cancers | human papillomavirus | treatment de‐escalation | Oropharyngeal cancers | Treatment de-escalation | Human papillomavirus | PD-1:PD-L1 immune checkpoint | SQUAMOUS-CELL-CARCINOMA | GYNECOLOGIC-ONCOLOGY-GROUP | INDUCTION CHEMOTHERAPY | treatment de-escalation | ROBOTIC SURGERY | HUMAN-PAPILLOMAVIRUS | INTRAEPITHELIAL NEOPLASIA | CANCER | PHASE-II TRIAL | ONCOLOGY | LOCALLY ADVANCED HEAD | SELECTIVE NECK DISSECTION | Oropharyngeal Neoplasms - therapy | Cancer Vaccines - therapeutic use | Papillomavirus Infections - complications | Humans | Oropharyngeal Neoplasms - etiology | Treatment Outcome | Clinical Trials as Topic | Combined Modality Therapy | Clinical trials | Papillomavirus infections | Squamous cell carcinoma | Laryngeal cancer | Cancer therapies | Index Medicus
Journal Article
British Journal of Haematology, ISSN 0007-1048, 04/2019, Volume 185, Issue 2, pp. 363 - 366
Journal Article
British Journal of Haematology, ISSN 0007-1048, 04/2019, Volume 185, Issue 2, pp. 370 - 373
Journal Article
Clinical Case Reports, ISSN 2050-0904, 11/2019, Volume 7, Issue 11, pp. 2156 - 2164
A 60‐year‐old woman with stage IV rectal cancer received adoptive cell therapy with autologous cancer antigen (AC‐ACT) causing induction of anti‐oncogenic and...
cancer | PD‐1 | adoptive cell therapy | miRNA analysis | immunotherapy
cancer | PD‐1 | adoptive cell therapy | miRNA analysis | immunotherapy
Journal Article